Dengue virus (DENV) infection has become a critically important globally prevalent infectious disease, especially in tropical and subtropical countries. Since neither currently exists, there is an urgent need for an effective vaccine to prevent, and a specific drug to treat DENV infection. Therapeutic peptides represent an attractive alternative for development into anti-DENV drugs due to their safety and their diverse biological and chemical properties. We recently reported novel bioactive peptides extracted from the Asian medicinal plant Acacia catechu that efficiently inhibited all four DENV serotypes. In this study, we investigated the anti-DENV activity of a synthetic bioactive peptide derived from this plant. The most effective peptide (designated Pep-RTYM) inhibited DENV infection with a half-maximal inhibition concentration value of 7.9 μM. Time-of-addition study demonstrated that Pep-RTYM interacted with DENV particles and inhibited cellular entry. Pep-RTYM at 50 μM significantly reduced DENV production in Vero-kidney epithelial cells about 1000-fold, but it could decrease the virus production in Huh7 hepatocyte cells approximately 40-fold. Binding of Pep-RTYM to DENV particles may prevent virus interaction with cellular receptor and subsequent virus entry. This finding suggests a potential role of Pep-RTYM in the development of a novel anti-DENV drug.This review aimed to map the existing patents of double-chamber syringes that can be used for intravenous drug administration and catheter flush. A search was conducted in the Google patents database for records published prior to 28 October 2020, using several search terms related to double-chamber syringes (DCS). Study eligibility and data extraction were performed by two independent reviewers. Of the initial 26,110 patents found, 24 were included in this review. The 24 DCS that were found display two or more independent chambers that allow for the administration of multiple solutions. While some of the DCS have designated one of the chambers as the flushing chamber, most patents only allow for the sequential use of the flushing chamber after intravenous drug administration. Most DCS were developed for drug reconstitution, usually with a freeze-dried drug in one chamber. Some patents were designed for safety purposes, with a parallel post-injection safety sheath chamber for enclosing a sharpened needle tip. None of the DCS found allow for a pre- and post-intravenous drug administration flush. Given the current standards of care in infusion therapy, future devices must allow for the sequential use of the flushing chamber to promote a pre-administration patency assessment and a post-administration device flush.In this paper, we propose mixed metal ions in the node of the zeolitic imidazolate framework (ZIF) structure. The hybrid metal ZIF is formed for the gas separation of hydrogen and carbon dioxide. In the first stage, the nanoparticles were prepared as a coating on a substrate, and acting as secondary growing nuclei. The hybrid metal ZIF structures were characterized by X-ray diffractometry (XRD) and Fourier transform infrared spectroscopy (FTIR). N2 adsorption-desorption isotherms determined surface area, and scanning electron microscopy (SEM) was used to observe the microstructure and surface morphology. The hybrid metal ZIF-8-67 powder had the largest surface area (1260.40 m2 g-1), and the nanoparticles (100 nm) could be fully dense-coated on the substrate to benefit the subsequent membrane growth. In the second stage, we prepared the hybrid metal ZIF-8-67 membrane on the pre-seeding substrate with mixed metal nanoparticles of cobalt and zinc, by the microwave hydrothermal method. Cobalt ions were identified in the tetrahedral coordination through UV-Vis, and the membrane structure and morphology were determined by XRD and SEM.  https://www.selleckchem.com/products/oicr-9429.html  Finally, a gas permeation analyzer (GPA) was used to determine the gas separation performance of the hybrid metal ZIF-8-67 membrane. We successfully introduced zinc ions and cobalt ions into the ZIF structure, where cobalt had a strong interaction with CO2. Therefore, GPA analysis showed an excellent H2/CO2 separation factor due to lower CO2 permeability. The CO2 permeance was ~0.65 × 10-8 mol m-2 s-1 Pa-1, and the separation factors for H2/CO2 and H2/N2 were 9.2 and 2.9, respectively. Our results demonstrate that the hybrid metal ZIF-8-67 membrane has a superior H2/CO2 separation factor, which can be attributed to its very high specific surface area and structure. Based on the above, hybrid metal ZIF-8-67 membranes are expected to be applied in hydrogen or carbon dioxide gas separation and purification.The human herpesvirus 6 (HHV-6) -A and -B are two dsDNA beta-herpesviruses infectingalmost the entire worldwide population. These viruses have been implicated in multipleneurological conditions in individuals of various ages and immunological status, includingencephalitis, epilepsy, and febrile seizures. HHV-6s have also been suggested as playing a role inthe etiology of neurodegenerative diseases such as multiple sclerosis and Alzheimer's disease. Theapparent robustness of these suggested associations is contingent on the accuracy of HHV-6detection in the nervous system. The effort of more than three decades of researching HHV-6 in thebrain has yielded numerous observations, albeit using variable technical approaches in terms oftissue preservation, detection techniques, sample sizes, brain regions, and comorbidities. In thisreview, we aimed to summarize current knowledge about the entry routes and direct presence ofHHV-6 in the brain parenchyma at the level of DNA, RNA, proteins, and specific cell types, inhealthy subjects and in those with neurological conditions. We also discuss recent findings relatedto the presence of HHV-6 in the brains of patients with Alzheimer's disease in light of availableevidence.Polyphenols, with anti-oxidant properties, counteract oxidative stress effects. Increasing evidence has found oxidative stressto be the main risk factor for trabecular meshwork (TM) damage, leading to high-tension glaucoma. Topical anti-oxidants could represent a new target for glaucoma treatment. Our aim is to investigate the protective mechanisms on a human TM culture of a patented polyphenol and fatty acid (iTRAB®)formulation in response to oxidative stress using an advanced invitromodel consisting of 3D-human TM cells, embedded in a natural hydrogel, and a milli-scaled multi-organ device model for constantdynamic conditions. The 3D-human TM cells(3D-HTMCs) were treated daily with 500 µM H2O2or 500 µM H2O2and 0.15% iTRAB®(m/v) for 72 h, and molecular differences in the intracellular reactive oxygen species (iROS), state of the cells, activation of the apoptosis pathway and NF-kB and the expression ofinflammatory and fibrotic markers wereanalyzed at different time-points.Concomitant exposure significantly reduced iROS and restored TM viability, iTRAB® having a significant inhibitory effect on the apoptotic pathway, activation of NF-κB, induction of pro-inflammatory (IL-1α, IL-1ß and TNFα) and pro-fibrotic (TGFβ) cytokines and the matrix metalloproteinase expressions.